IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook Third quarter revenue of $2,786 million and Adjusted EBITDA of $604 million GAAP Diluted Earnings per Share of $0.52 and

Third quarter revenue of $2,786 million and Adjusted EBITDA of $604 million

GAAP Diluted Earnings per Share of $0.52 and Adjusted Diluted Earnings per Share of $1.63

Technology & Analytics Solutions revenue grew 10.2 percent reported and 9.2 percent on a constant currency basis

R&D Solutions quarterly net book-to-bill ratio was 1.71x; next twelve months revenue from backlog increased over $400 million to $5.8 billion

Full-year 2020 guidance raised for revenue, Adjusted EBITDA and Adjusted Diluted EPS

Full-year 2021 outlook for revenue $12,300 million to $12,600 million, Adjusted EBITDA $2,725 million to $2,800 million and Adjusted Diluted EPS $7.65 to $7.95

Company to resume share repurchase program

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--October 20, 2020--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the

life sciences industry, today reported financial results for the quarter ended September 30, 2020.

Third-Quarter 2020 Operating Results

Revenue for the third quarter of $2,786 million increased 0.6 percent on a reported basis and was lower by 0.1 percent at constant currency, compared to the third quarter of 2019. Technology & Analytics Solutions (TAS) revenue of

$1,207 million grew 10.2 percent reported and 9.2 percent on a constant currency basis. Research & Development Solutions (R&DS) revenue of $1,400 million was lower by 4.5 percent on a reported basis and by 5.1 percent at constant

currency. Excluding the impact of pass throughs, R&DS revenue grew 2.6 percent year-over-year on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $179 million was lower by 13.9 percent on a reported basis and

by 14.4 percent at constant currency.

R&DS contracted backlog, including reimbursed expenses, grew 18.5 percent year-over-year to $21.7 billion at September 30, 2020. The company expects approximately $5.8 billion of this backlog to convert to revenue in the next twelve

months, up from $5.4 billion at June 30, 2020. The third quarter contracted net book-to-bill ratio was 1.71x including reimbursed expenses and 1.42x excluding reimbursed expenses. For the last twelve months ended September 30, 2020, the

contracted net book-to-bill ratio was 1.55x including reimbursed expenses and 1.45x excluding reimbursed expenses.

Third-quarter 2020 Adjusted EBITDA was $604 million, up 1.9 percent compared to the third quarter of 2019. GAAP net income was $101 million, and GAAP diluted earnings per share was $0.52. Adjusted Net Income was $318 million and

Adjusted Diluted Earnings per Share was $1.63, up 1.9 percent compared to the third quarter of 2019.

"The IQVIA team continues to execute well in the current environment, once again delivering results above our financial targets, with revenue and profit metrics turning positive in the third quarter," said Ari Bousbib, chairman and CEO

of IQVIA. "TAS has already returned to pre-COVID growth rates and R&DS is expected to reach double-digit growth in the fourth quarter. Demand remains robust, as evidenced by another record quarter of bookings in R&DS, setting the

stage for an excellent 2021."

Year-to-Date 2020 Operating Results

Revenue of $8,061 million for the first nine months of 2020 was lower by 1.6 percent reported and by 1.2 percent at constant currency, compared to the first nine months of 2019. TAS revenue of $3,433 million grew 4.9 percent reported

and 5.6 percent at constant currency. R&DS revenue of $4,076 million was lower by 5.6 percent reported and by 5.4 percent at constant currency. CSMS revenue of $552 million was lower by 8.6 percent reported and by 8.3 percent at

Adjusted EBITDA for the first nine months of 2020 was $1,649 million. GAAP net income was $160 million and GAAP diluted earnings per share was $0.82. Adjusted Net Income was $841 million and Adjusted Diluted Earnings per Share was

As of September 30, 2020, cash and cash equivalents were $1,464 million and debt was $12,339 million, resulting in net debt of $10,875 million. At the end of the third quarter of 2020, IQVIA's Net Leverage Ratio was 4.7x trailing

twelve month Adjusted EBITDA.

When the COVID-19 outbreak became a pandemic in March, the company temporarily suspended share repurchase activity. Based on the company's performance during the pandemic, continued robust demand for its offerings, solid liquidity,

and strong free cash flow performance, IQVIA is today lifting the temporary suspension of its share repurchase program. As of September 30, 2020, the company had approximately $1.0 billion of share repurchase authorization remaining.

Full-Year 2020 Guidance

For the full year of 2020, the company is raising its guidance ranges as follows:

Fourth-Quarter 2020 Guidance

For the fourth quarter of 2020, the company is providing guidance as follows:

Guidance for the fourth quarter and full year of 2020 assumes that business conditions will continue to improve and that localized flare ups of COVID-19 will not have a material impact to fourth quarter results.

Full-Year 2021 Outlook

For the full year of 2021, the company expects revenue of between $12,300 million and $12,600 million, Adjusted EBITDA of between $2,725 million and $2,800 million, and Adjusted Diluted Earnings per Share of between $7.65 and $7.95.

The company will provide more detailed full-year 2021 guidance on its fourth quarter earnings results call in mid-February 2021.

The company has developed this outlook based on the general assumption of continued recovery and return to normal business conditions in 2021. The company further assumes that there will not be another global wave of COVID-19 infection

that would lead to public health policy decisions that could cause widespread business and healthcare disruptions, hampering the progress of sites reopening, patients returning to trials or other face-to-face interactions that are

important to our business.

All financial guidance assumes foreign currency exchange rates at September 30, 2020 remain in effect for the periods forecasted.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its third quarter 2020 results and full-year 2020 and 2021 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA

Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email

containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the

confirmation email and will be placed directly into the call.

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data

science - leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science - to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation

and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE , IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well

as execution capabilities. With approximately 68,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that

helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical

companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn

more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended, including, without limitation, our fourth quarter 2020 and full-year 2020 and 2021 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition,

and often contain words such as "expect," "assume," "anticipate," "intend," "plan," "forecast," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Actual results may

differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak and the public

health policy responses to the outbreak, international conflicts or other disruptions outside of our control; our ability to accurately model or forecast the impact of the spread and/or containment of COVID-19, among other sources of

business interruption, on our operations and financial results; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market

for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any

failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners' security or

communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to

claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and

formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which

our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration;

government regulators or our customers may limit the scope of prescription or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical

industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic

conditions in the markets in which we operate, including financial market conditions and risks related to sales to government entities; the impact of changes in tax laws and regulations; our ability to successfully integrate, and achieve

expected benefits from, our acquired businesses; and risks and uncertainty associated with providing guidance and forecasts earlier than is our customary practice. For a further discussion of the risks relating to the combined company's

business, see the "Risk Factors" in our annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC, as such factors may be amended or updated from time to time in our subsequent periodic and other filings

with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in

our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

Non-GAAP results, such as Adjusted EBITDA, Adjusted Net Income, and Adjusted Diluted EPS are presented only as a supplement to the company's financial statements based on GAAP. Non-GAAP financial information is provided to enhance

understanding of the company's financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the

company's results of operations as determined in accordance with GAAP. Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are provided within the schedules attached to this release. The

company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating

performance of the business. For example, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements and trademarks, trade names and other

from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it

is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to IQVIA Holdings Inc. As a result, internal management reports feature non-GAAP

measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors

are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

Our full-year 2020 and 2021 guidance measures (other than revenue) are provided on a non-GAAP basis because the company is unable to reasonably predict certain items contained in the GAAP measures. Such items include, but are not

limited to, acquisition and integration related expenses, restructuring and related charges, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results.

Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for

the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not

consider such performance measures in isolation from, or as a substitute analysis for, the company's results of operations as determined in accordance with GAAP.